Tyra Biosciences (TYRA) Total Current Liabilities (2020 - 2026)

Tyra Biosciences has reported Total Current Liabilities for 7 years, with the latest figure at $19.3 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 35.17% year-over-year to $19.3 million; the trailing twelve-month figure through Mar 2026 stood at $19.3 million (up 35.17% YoY), and the FY2025 full-year result was $18.1 million, up 23.98% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $19.3 million, up from $18.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $19.3 million in Q1 2026, with the low at $3.7 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $10.8 million across 5 years, with a median of $10.4 million in 2024.
• The largest YoY upside for Total Current Liabilities was 168.95% in 2023 against a maximum downside of 24.87% in 2023.
• Tyra Biosciences' Total Current Liabilities stood at $5.7 million in 2022, then soared by 168.95% to $15.3 million in 2023, then slipped by 4.82% to $14.6 million in 2024, then rose by 23.98% to $18.1 million in 2025, then rose by 6.42% to $19.3 million in 2026.
• The last three Total Current Liabilities figures came in at $19.3 million (Q1 2026), $18.1 million (Q4 2025), and $15.9 million (Q3 2025), per Business Quant data.